1887
  1. Home
  2. Eurosurveillance
  3. Volume 22, Issue 2, 12/Jan/2017
  4. Article
Surveillance and outbreak report Open Access
Like 0
This item has no PDF Download

Abstract

To enable an up-to-date molecular analysis of human immunodeficiency virus (HIV) genotypes circulating in Germany we have established a surveillance system based on recently acquired HIV infections. New HIV infections are reported to the Robert Koch Institute as a statutory duty for anonymous notification. In 2013 and 2014, a dried serum spot (DSS) sample was received from 6,371 newly diagnosed HIV-cases; their analysis suggested that 1,797 samples originated from a recent infection. Of these, 809 were successfully genotyped in the region to identify transmitted drug resistance (TDR) mutations and to determine the HIV-1 subtype. Total TDR was 10.8%, comprising 4.3% with mono-resistance to nucleoside reverse transcriptase inhibitors (NRTIs), 2.6% to non-NRTIs, 3.0% to protease inhibitors and 0.6% and 0.2%, respectively, with dual- and triple-class resistances. HIV-1 subtype B was most prevalent with 77.0%. Non-B infections were identified more often in men and women with heterosexual transmission compared with intravenous drug users or men who have sex with men (79% and 76%, 33%, 12%; all p < 0.05). Non-B subtypes were also more frequently found in patients originating from countries other than Germany (46% vs 14%; p < 0.05) and in patients infected outside of Germany (63% vs 14%; p < 0.05).

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2017.22.2.30436
2017-01-12
2024-12-28
/content/10.2807/1560-7917.ES.2017.22.2.30436
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/22/2/eurosurv-22-30436-3.html?itemId=/content/10.2807/1560-7917.ES.2017.22.2.30436&mimeType=html&fmt=ahah

References

  1. Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363-71.  https://doi.org/10.1016/S1473-3099(11)70032-9  PMID: 21354861 
  2. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203-12.  https://doi.org/10.1097/QAD.0b013e3283388742  PMID: 20395786 
  3. Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, Micheli V, et al. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol Infect. 2012;18(8):E299-304.  https://doi.org/10.1111/j.1469-0691.2012.03847.x  PMID: 22536753 
  4. Baxter JD, Dunn D, White E, Sharma S, Geretti AM, Kozal MJ, et al. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(Suppl 1):77-87.  https://doi.org/10.1111/hiv.12236  PMID: 25711326 
  5. Zu Knyphausen F, Scheufele R, Kücherer C, Jansen K, Somogyi S, Dupke S, et al. First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study. PLoS One. 2014;9(5):e95956.  https://doi.org/10.1371/journal.pone.0095956  PMID: 24788613 
  6. Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014;14(1):407.  https://doi.org/10.1186/1471-2334-14-407  PMID: 25047543 
  7. European AIDS Clinical Society (EACS). Guidelines. Version 8.0. European Guidelines for treatment of HIV-infected adults in Europe2015. Brussels: EACS; October 2015. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
  8. Yang WL, Kouyos RD, Böni J, Yerly S, Klimkait T, Aubert V, et al. , Swiss HIV Cohort Study (SHCS). Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds. PLoS Pathog. 2015;11(3):e1004722.  https://doi.org/10.1371/journal.ppat.1004722  PMID: 25798934 
  9. Cleland A, Davis C, Adams N, Lycett C, Jarvis LM, Holmes H, et al. Development of multiplexed nucleic acid testing for human immunodeficiency virus type 1 and hepatitis C virus. Vox Sang. 2001;81(2):93-101.  https://doi.org/10.1046/j.1423-0410.2001.00093.x  PMID: 11555468 
  10. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42(18):e144.  https://doi.org/10.1093/nar/gku739  PMID: 25120265 
  11. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724.  https://doi.org/10.1371/journal.pone.0004724  PMID: 19266092 
  12. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016;62(5):655-63.  https://doi.org/10.1093/cid/civ963  PMID: 26620652 
  13. Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA, UK HIV Drug Resistance Database. Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the United Kingdom. Clin Infect Dis. 2015;61(5):829-36.  https://doi.org/10.1093/cid/civ393  PMID: 25991470 
  14. Karlsson A, Björkman P, Bratt G, Ekvall H, Gisslén M, Sönnerborg A, et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One. 2012;7(3):e33484.  https://doi.org/10.1371/journal.pone.0033484  PMID: 22448246 
  15. Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, Albert J, et al. The global spread of HIV-1 subtype B epidemic. Infect Genet Evol. 2016;46:169-79.
  16. Pereira NR, Duro R, Piñero C, Malheiro L, Soares J, Serrão R, et al. Characterization of HIV-1 subtypes in a Portuguese cohort. J Int AIDS Soc. 2014;17(4) Suppl 3;19683. PMID: 25397433 
  17. Abecasis AB, Wensing AM, Paraskevis D, Vercauteren J, Theys K, Van de Vijver DA, et al. HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology. 2013;10(1):7.  https://doi.org/10.1186/1742-4690-10-7  PMID: 23317093 
  18. Foley B, Pan H, Buchbinder S, Delwart EL. Apparent founder effect during the early years of the San Francisco HIV type 1 epidemic (1978-1979). AIDS Res Hum Retroviruses. 2000;16(15):1463-9.  https://doi.org/10.1089/088922200750005985  PMID: 11054259 
  19. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20(16):W13-23.  https://doi.org/10.1097/01.aids.0000247564.73009.bc  PMID: 17053344 
  20. Robert Koch Institute (RKI). Regional distribution of new HIV diagnoses within Germany. [Regionale Verteilung der HIV-Neudiagnosen innerhalb Deutschlands]. Epidemiologisches Bulletin. 2015;27/2015. German. Available from: http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/27_15.pdf?__blob=publicationFile.
  21. Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS. 2014;28(16):2439-49.  https://doi.org/10.1097/QAD.0000000000000429  PMID: 25144218 
  22. European Centre for Disease Prevention and Control (ECDC). Monitoring recently acquired HIV infections in the European context. Stockholm: ECDC; 2013. Available from: http://www.ecdc.europa.eu/en/publications/Publications/monitoring-recently-acquired-HIV-infections-european-context.pdf
  23. Kim AA, McDougal JS, Hargrove J, Rehle T, Pillay-Van Wyk V, Puren A, et al. Evaluating the BED capture enzyme immunoassay to estimate HIV incidence among adults in three countries in sub-Saharan Africa. AIDS Res Hum Retroviruses. 2010;26(10):1051-61.  https://doi.org/10.1089/aid.2009.0218  PMID: 20849299 
  24. Scheer S, Nakelsky S, Bingham T, Damesyn M, Sun D, Chin CS, et al. Estimated HIV Incidence in California, 2006-2009. PLoS One. 2013;8(2):e55002.  https://doi.org/10.1371/journal.pone.0055002  PMID: 23405106 
  25. Grinberg G, Giron LB, Knoll RK, Galinskas J, Camargo M, Arif MS, et al. High prevalence and incidence of HIV-1 in a counseling and testing center in the city of Itajaí, Brazil. Braz J Infect Dis. 2015;19(6):631-5.  https://doi.org/10.1016/j.bjid.2015.08.001  PMID: 26361837 
  26. Zhang J, Guo Z, Yang J, Pan X, Jiang J, Ding X, et al. Genetic diversity of HIV-1 and transmitted drug resistance among newly diagnosed individuals with HIV infection in Hangzhou, China. J Med Virol. 2015;87(10):1668-76.  https://doi.org/10.1002/jmv.24223  PMID: 25899877 
  27. Lunar MM, Matković I, Tomažič J, Vovko TD, Pečavar B, Poljak M. Longitudinal trends of recent HIV-1 infections in Slovenia (1986-2012) determined using an incidence algorithm. J Med Virol. 2015;87(9):1510-6.  https://doi.org/10.1002/jmv.24209  PMID: 25970253 
  28. Santos-Hövener C, Zimmermann R, Kücherer C, Bätzing-Feigenbaum J, Wildner S, Hamouda O, et al. Conversation about Serostatus decreases risk of acquiring HIV: results from a case control study comparing MSM with recent HIV infection and HIV negative controls. BMC Public Health. 2014;14(1):453.  https://doi.org/10.1186/1471-2458-14-453  PMID: 24885694 
  29. Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis. 2010;50(1):98-105.  https://doi.org/10.1086/648729  PMID: 19951169 
  30. Drescher SM, von Wyl V, Yang WL, Böni J, Yerly S, Shah C, et al. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis. 2014;58(2):285-94.  https://doi.org/10.1093/cid/cit694  PMID: 24145874 
National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Andrea+Hauser&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hauser Andrea</a>, <a href="/search?value1=Alexandra+Hofmann&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hofmann Alexandra</a>, <a href="/search?value1=Kirsten+Hanke&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hanke Kirsten</a>, <a href="/search?value1=Viviane+Bremer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bremer Viviane</a>, <a href="/search?value1=Barbara+Bartmeyer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bartmeyer Barbara</a>, <a href="/search?value1=Claudia+Kuecherer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kuecherer Claudia</a>, <a href="/search?value1=Norbert+Bannert&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bannert Norbert</a></span>. National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014. <a href="/content/ecdc">Euro Surveill.</a> 2017;22(2):pii=30436. <a href="https://doi.org/10.2807/1560-7917.ES.2017.22.2.30436" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2017.22.2.30436</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 01 Feb 2016;&nbsp;&nbsp; <span class="generated">Accepted</span>: 23 Aug 2016 </span> </p>
/content/10.2807/1560-7917.ES.2017.22.2.30436
/content/10.2807/1560-7917.ES.2017.22.2.30436
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error